** Amplia Therapeutics ATX.AX slips as much as 14% to A$0.245, lowest since July 4
** Stock marks biggest intraday pct drop since June 30
** Drug developer announces capital raise of A$27.5 mln ($18 mln) at issue price of A$0.23, representing 19.3% discount to last close
** Says funds will support ACCENT and AMPLICITY trials, support ovarian cancer trials of co's lead drug, narmafotinib (AMP945
** Stock last down 10.5%, trims YTD gains to ~192%
($1 = A$1.5253)
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。